Human VEGF-C ELISA Kit

Kit Components

 1. RecombinantHuman VEGF-C standard: 2 vials

 2. One 96-well plate precoated with anti-Human VEGF-C Ab

 3. Sample diluent buffer: 12 mL - 1

 4. Detection antibody: 130 µL, dilution 1:100

 5. Streptavidin-HRP: 130 µL, dilution 1:100

 6. Antibody diluent buffer: 12 mL x1   

 7. Streptavidin-HRP diluent buffer: 12 mL x1

 8. TMB developing agent: 10 mL x1

9. Stop solution: 10 mL x1.

10. Washing solution (20x): 25 mL x1.

Background

The Vascular Endothelial Growth Factors (VEGFs) including VEGF-A, -B, -C, -D, -E and Placenta Growth Factor (PlGF), play important roles in vascular and lymphatic vessel growth. VEGF-C, also known as Flt4 ligand (Flt4-L), or vascular endothelial growth factor-related protein (VRP), has the conserved VEGF homology domain (VHD) and is characteristic of long N- and C-terminal extensions. VEGF-C is expressed primarily in lymph nodes, heart, placenta, ovary, and small intestine. VEGF-C binds and activates VEGF R2 and VEGF R3 to transduce its signals in the target cells. It has been shown that a number of proteolytically processed VEGF-C isoforms can bind VEGF R3 with different affinity, only the mature VEGF-C can bind VEGF R2. The Integrin α9β1 and the Semaphorin/VEGF family receptor Neuropilin-2 may also act as receptors or co-receptors for VEGF-C. VEGF-C induces vascular permeability through the activation of VEGF R2. VEGF-C and VEGF R3 are co-expressed at sites of lymphatic vessel sprouting in the embryo, the VEGF-C/VEGF R3 signaling pathway is crucial to lymphangiogenesis. Elevated VEGF-C levels have been correlated with many human cancers. Increased VEGF-C-mediated lymphangiogenesis and metastases are observed in several models of human cancer, suggesting that overexpression of VEGF-C might be a predictor of lymph node metastases.